

Dataset Integrity Check for the Diabetes Prevention Program Outcomes Study Phase 1 Data Files



Prepared by

RTI International
3040 Cornwallis Road
Research Triangle Park, NC 27709-2194
March, 2013

Revision History

Version	Author/Title	Date	Comments
1.0	Norma Pugh	March, 2013	Original

Table of Contents

Contents

1	Standard Disclaimer	1
2	Study Background	1
3	Archived Datasets.....	2
4	Statistical Methods	3
5	Results	3
6	Conclusions	3
7	References	4
	Attachment A: SAS Code, provided by DCC and modified by RTI	10
	Attachment B: SAS Output, from code provided by DCC and modified by RTI.	15
	Attachment C: SAS Code, written by RTI.....	21
	Attachment D: SAS Output, from code written by RTI.	23
	Table A: Variables Used to Replicate Selected Statistics from Results Section of Publication.....	5
	Table B: Comparison of Values Computed in Integrity Check to Reference Article Selected Statistical Values.	6
	Table B: Comparison of Values Computed in Integrity Check to Reference Article Selected Statistical Values, continued.	7
	Table B: Comparison of Values Computed in Integrity Check to Reference Article Selected Statistical Values, continued.	8
	Table B: Comparison of Values Computed in Integrity Check to Reference Article Selected Statistical Values, continued.	9

1 Standard Disclaimer

The intent of this DSIC is to provide confidence that the data distributed by the NIDDK repository is a true copy of the study data. Our intent is not to assess the integrity of the statistical analyses reported by study investigators. As with all statistical analyses of complex datasets, complete replication of a set of statistical results should not be expected on a first (or second) exercise in secondary analysis. This occurs for a number of reasons including differences in the handling of missing data, restrictions on cases included in samples for a particular analysis, software coding used to define complex variables, etc. Experience suggests that most discrepancies can ordinarily be resolved by consultation with the study data coordinating center (DCC); however, this process is labor-intensive for both DCC and Repository staff. It is thus not our policy to resolve every discrepancy that is observed in an integrity check. Specifically, we do not attempt to resolve minor or inconsequential discrepancies with published results or discrepancies that involve complex analyses, *unless NIDDK Repository staff suspect that the observed discrepancy suggests that the dataset may have been corrupted in storage, transmission, or processing by repository staff*. We do, however, document in footnotes to the integrity check those instances in which our secondary analyses produced results that were not fully consistent with those reported in the target publication.

2 Study Background

The Diabetes Prevention Program (DPP) was a major multicenter clinical research study aimed at discovering whether modest weight loss through dietary changes and increased physical activity or treatment with the oral diabetes drug metformin (Glucophage) could prevent or delay the onset of type 2 diabetes in study participants. At the beginning of the DPP, participants were all overweight and had prediabetes [1].

The DPP found that participants who lost a modest amount of weight through dietary changes and increased physical activity sharply reduced their chances of developing diabetes. Taking metformin also reduced risk, although less dramatically. The DPP resolved its research questions earlier than projected and, following the recommendation of an external monitoring board, the study was halted a year early. The researchers published their findings in the February 7, 2002, issue of the New England Journal of Medicine [1], [2].

Following unblinding of the Diabetes Prevention Program (DPP) results, a 16-session lifestyle intervention program (DPP Bridge) was offered to all study participants, including those who had initially

been randomized to lifestyle treatment. Venditti et al. compare the effects of the lifestyle program between participants who had previous exposure and those who had not [3].

Following DPP Bridge, the Diabetes Prevention Program Outcomes Study (DPPOS Phase 1) protocol was initiated. Lifestyle sessions were offered to all participants every 3 months. DPP lifestyle participants were also offered two group classes, each comprising four sessions per year. Those previously assigned to the metformin group continued the drug, now unmasked, as tolerated, unless the drug was discontinued for protocol or safety reasons. Outcome assessment examinations continued on the same yearly and 6 monthly schedule as in the DPP. DPP results concluded that diabetes incidence in high-risk adults was reduced by 58% with intensive lifestyle intervention and by 31% with metaformin, compared with placebo. Knowler et al. investigate the long term (10-year follow-up) persistence of these effects [2], [3].

3 Archived Datasets

Original DPP Data: All SAS data files, as provided by the Data Coordinating Center (DCC), are located in the DPP data folder in the “v2.1\Data\DPP_Data_2008\Form Data\Data” and “v2.1\Data\DPP_Data_2008\Non-Form Data\Data” sub-folders of the Official Archive. Only clinics and participants with IRB approval and informed consent to distribute their data to the repository are included. Out of the 3,819 original DPP participants, 3,665 participants are included in this release dataset [4].

Bridge Data: All SAS data files, as provided by the Data Coordinating Center (DCC), are located in the DPP Bridge data folder in the “DPP_Bridge_Official_Archive\DPP_BRIDGE_Data\Form_based” and “DPP_Bridge_Official_Archive\DPP_BRIDGE_Data\non_form_based” sub-folders of the Official Archive. Only clinics and participants with IRB approval and informed consent to distribute their data to the repository are included. Out of the 3,819 DPP participants, 3,655 are included in the DPP Bridge datasets [5].

Outcomes Study (Phase 1) Data: All SAS data files, as provided by the Data Coordinating Center (DCC), are located in the DPPOS Phase 1 data folder in the “DPPOS_PHASE1_Data\form-based” and “DPPOS_PHASE1_Data\non-form-based” sub-folders of the Official Archive. Only clinics and participants with IRB approval and informed consent to distribute their data to the repository are included. Out of the 3,250 participants who consented to DPPOS Phase 1, there are 3,049 participants included in this release dataset [6].

4 Statistical Methods

The DCC created archived datasets separately by study phase (DPP, DPP Bridge, and DPPOS Phase 1), and provided code to be used to correctly merge the 3 sets of data. That code was then modified by the Repository statistician to run on the data files housed at the repository. The code was tested and analyses were run to verify the integrity of the data.

Analyses include:

1. Weight at each semi-annual visit by treatment arm, for the full DPP + Bridge + Phase 1 period.
2. Cox proportional hazards model (Time to Diabetes) for the full DPP + Bridge + Phase 1 period.
3. Cox proportional hazards model (Time to Diabetes) for the DPP period only.

The complete SAS program and resulting output are included in Attachments A and B.

Additionally, we replicated selected variables published by Knowler et al. [2] in the Lancet, 2009. The SAS program and resulting output for this replication are included in Attachments C and D.

5 Results

Selected statistics cover a variety of demographic and laboratory values. Our Table A lists the variables we used in our replication. Table B compares the results calculated from the archived data file to the published results. The results of this replication are quite similar to the published results. Note that the DPP data deposited in the Repository exclude a small subset of DPP participants who did not consent to making their data available in the Repository. Thus, we did not expect exact replication of statistics from published studies.

6 Conclusions

Based on our Dataset Integrity Checks of previous datasets from the DPP studies, in addition to these subsequent analyses of the DPP Bridge and Phase 1 data files, we have every reason to believe that the DPP Phase 1 data files distributed by the NIDDK Repository are true copies of the study data.

7 References

1. National Diabetes Information Clearinghouse (NDIC) website:
<http://diabetes.niddk.nih.gov/dm/pubs/preventionprogram/index.aspx>
2. Diabetes Prevention Program Research Group, Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *New England Journal of Medicine*, 2002 Feb 7; 346(6):393-403.
3. E.M. Venditti, et al. (2008) First versus repeat treatment with a lifestyle intervention program: attendance and weight loss outcomes. *International Journal of Obesity*; 2008 Oct; 32(10):1537-44.
4. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Data Coordinating Center (DCC) (2012) DPP Phase 1 Documentation, stored in the “DPPOS_PHASE1_Documentations” folder.
5. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Data Coordinating Center (DCC) (2012) DPP Documentation, stored in the “Official_Archive\2.1\Documentation\DPP_2008_Data_Release_Docs” folder.
6. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Data Coordinating Center (DCC) (2012) DPP Phase 1 Documentation, stored in the “DPPOS_PHASE1_Documentations” folder.

Table A: Variables Used to Replicate Selected Statistics from Results Section of Publication.

Publication Variable	Dataset: Variables Used in Replication
Total sample size	demographic: assign^= 'Troglitazone'
Fasting plasma glucose	laboratory: g000*0.055
HbA _{1c}	laboratory: hba1
Gender	demographic: sex (1=men, 2=women)
Diabetes status	events: diabf (0=no, 1=yes)
2-h plasma glucose	laboratory: g120*0.055
Cholesterol	laboratory: chol*0.0259
HDL cholesterol	laboratory: chdl*0.0259
LDL cholesterol	laboratory: cldl*0.0259
Triglycerides	laboratory: trig*0.0113

DPP Phase 1: ADDENDUM

Table B: Comparison of Values Computed in Integrity Check to Reference Article Selected Statistical Values.

Treatment = All Values

Characteristic	Knowler	Integrity Check	Difference
Sample size, n	2766	2572	-194
Fasting plasma glucose (mmol/L)	6.03 (1.10)	6.04 (1.16)	+0.01 (+0.06)
HbA _{1c} (%)	5.95 (0.69)	5.94 (0.68)	-0.01 (-0.01)
Men	888	859	-29
Women	1878	1713	-165
Without diabetes (n)			
Fasting plasma glucose (mmol/L)	5.72 (0.52)	5.58 (0.49)	-0.14 (-0.03)
2-h plasma glucose (mmol/L)	8.11 (1.92)	7.68 (1.82)	-0.43 (-0.10)
HbA _{1c} (%)	5.78 (0.46)	5.69 (0.37)	-0.09 (-0.09)
Cholesterol (mmol/L)	5.08 (0.90)	5.07 (0.93)	-0.01 (+0.03)
HDL cholesterol (mmol/L)	1.23 (0.33)	1.28 (0.35)	+0.05 (+0.02)
LDL cholesterol (mmol/L)	3.11 (0.80)	3.09 (0.80)	-0.02 (0)
Triglycerides (mmol/L)	1.38 (0.98-1.98)	1.29 (0.93-1.88)	-0.07 (-0.05,-0.10)
With diabetes (n)			
Fasting plasma glucose (mmol/L)	6.83 (1.65)	6.57 (1.44)	-0.26 (-0.21)
HbA _{1c} (%)	6.38 (0.96)	6.22 (0.84)	-0.16 (-0.12)
Cholesterol (mmol/L)	5.00 (0.88)	5.03 (1.09)	+0.03 (-0.21)
HDL cholesterol (mmol/L)	1.14 (0.29)	1.18 (0.31)	+0.04 (+0.02)
LDL cholesterol (mmol/L)	3.02 (0.78)	3.03 (0.81)	+0.01 (+0.03)
Triglycerides (mmol/L)	1.60 (1.11-2.16)	1.51 (1.11-2.14)	-0.09 (0,-0.02)

*Data are mean (SD) apart from triglycerides for which data are median (IQR), or number of participants (n).

DPP Phase 1: ADDENDUM

Table C: Comparison of Values Computed in Integrity Check to Reference Article Selected Statistical Values, continued.

Treatment = ILS

Characteristic	Knowler	Integrity Check	Difference
Sample size, n	910	847	-63
Fasting plasma glucose (mmol/L)	5.98 (0.98)	5.99 (1.2)	+0.01 (+0.04)
HbA _{1c} (%)	5.89 (0.64)	5.90 (0.66)	+0.01 (+0.02)
Men	291	283	-8
Women	619	564	-55
Without diabetes (n)			
Fasting plasma glucose (mmol/L)	5.72 (0.51)	5.57 (0.52)	-0.15 (+0.01)
2-h plasma glucose (mmol/L)	7.98 (1.92)	7.65 (1.78)	-0.33 (-0.14)
HbA _{1c} (%)	5.75 (0.48)	5.69 (0.38)	-0.06 (-0.10)
Cholesterol (mmol/L)	5.08 (0.91)	5.08 (0.94)	0 (+0.03)
HDL cholesterol (mmol/L)	1.25 (0.34)	1.30 (0.37)	+0.05 (+0.03)
LDL cholesterol (mmol/L)	3.12 (0.80)	3.10 (0.81)	-0.02 (+0.01)
Triglycerides (mmol/L)	1.31 (0.93-1.89)	1.22 (0.88-1.83)	-0.09 (-0.05,-0.06)
With diabetes (n)			
Fasting plasma glucose (mmol/L)	7.10 (1.56)	6.61 (1.50)	-0.49 (-0.06)
HbA _{1c} (%)	6.47 (0.88)	6.20 (0.83)	-0.27 (-0.05)
Cholesterol (mmol/L)	5.05 (0.88)	5.03 (0.95)	-0.02 (+0.07)
HDL cholesterol (mmol/L)	1.12 (0.29)	1.15 (0.29)	+0.03 (0)
LDL cholesterol (mmol/L)	3.07 (0.76)	3.07 (0.81)	0 (+0.05)
Triglycerides (mmol/L)	1.57 (1.16-2.20)	1.56 (1.13-2.08)	-0.01 (-0.03,-0.12)

*Data are mean (SD) apart from triglycerides for which data are median (IQR), or number of participants (n).

DPP Phase 1: ADDENDUM

Table D: Comparison of Values Computed in Integrity Check to Reference Article Selected Statistical Values, continued.

Treatment = Metformin

Characteristic	Knowler	Integrity Check	Difference
Sample size, n	924	864	-60
Fasting plasma glucose (mmol/L)	5.94 (1.04)	5.92 (0.97)	-0.02 (-0.07)
HbA _{1c} (%)	5.94 (0.63)	5.89 (0.64)	-0.05 (+0.01)
Men	307	296	-11
Women	617	568	-49
Without diabetes (n)			
Fasting plasma glucose (mmol/L)	5.66 (0.53)	5.56 (0.48)	-0.10 (-0.05)
2-h plasma glucose (mmol/L)	8.19 (2.02)	7.79 (1.88)	-0.40 (-0.14)
HbA _{1c} (%)	5.79 (0.43)	5.69 (0.34)	-0.10 (-0.09)
Cholesterol (mmol/L)	5.07 (0.86)	5.06 (0.86)	-0.01 (0)
HDL cholesterol (mmol/L)	1.23 (0.34)	1.28 (0.35)	+0.05 (+0.01)
LDL cholesterol (mmol/L)	3.08 (0.75)	3.07 (0.73)	-0.01 (-0.02)
Triglycerides (mmol/L)	1.41 (1.02-2.00)	1.36 (0.95-1.93)	-0.05 (-0.07,-0.07)
With diabetes (n)			
Fasting plasma glucose (mmol/L)	6.61 (1.54)	6.34 (1.21)	-0.27 (-0.33)
HbA _{1c} (%)	6.30 (0.85)	6.14 (0.80)	-0.16 (-0.05)
Cholesterol (mmol/L)	4.99 (0.89)	4.99 (0.89)	0
HDL cholesterol (mmol/L)	1.20 (0.30)	1.21 (0.30)	+0.01 (0)
LDL cholesterol (mmol/L)	2.98 (0.78)	2.99 (0.80)	+0.01 (+0.02)
Triglycerides (mmol/L)	1.51 (1.12-2.14)	1.47 (1.07-2.18)	-0.04 (-0.05,+0.04)

*Data are mean (SD) apart from triglycerides for which data are median (IQR), or number of participants (n).

Table E: Comparison of Values Computed in Integrity Check to Reference Article Selected Statistical Values, continued.**Treatment = Placebo**

Characteristic	Knowler	Integrity Check	Difference
Sample size, n	932	861	-71
Fasting plasma glucose (mmol/L)	6.18 (1.24)	6.20 (1.30)	+0.02 (+0.06)
HbA _{1c} (%)	6.01 (0.79)	6.01 (0.74)	0 (-0.05)
Men	290	280	-10
Women	642	581	-61
Without diabetes (n)			
Fasting plasma glucose (mmol/L)	5.79 (0.51)	5.61 (0.45)	-0.18 (-0.06)
2-h plasma glucose (mmol/L)	8.20 (1.78)	7.61 (1.79)	-0.59 (+0.01)
HbA _{1c} (%)	5.80 (0.46)	5.71 (0.38)	-0.09 (-0.08)
Cholesterol (mmol/L)	5.08 (0.93)	5.09 (1.00)	+0.01 (+0.07)
HDL cholesterol (mmol/L)	1.19 (0.31)	1.26 (0.33)	+0.07 (+0.02)
LDL cholesterol (mmol/L)	3.12 (0.85)	3.11 (0.85)	-0.01 (0)
Triglycerides (mmol/L)	1.43 (1.03-2.01)	1.36 (0.97-1.86)	-0.07 (-0.06,-0.15)
With diabetes (n)			
Fasting plasma glucose (mmol/L)	6.88 (1.76)	6.75 (1.56)	-0.13 (-0.20)
HbA _{1c} (%)	6.40 (1.07)	6.30 (0.86)	-0.10 (-0.21)
Cholesterol (mmol/L)	4.98 (0.88)	5.06 (1.33)	+0.08 (+0.45)
HDL cholesterol (mmol/L)	1.11 (0.28)	1.16 (0.33)	+0.05 (+0.05)
LDL cholesterol (mmol/L)	3.02 (0.80)	3.04 (0.83)	+0.02 (+0.03)
Triglycerides (mmol/L)	1.65 (1.08-2.21)	1.53 (1.14-2.14)	-0.08 (+0.06,-0.07)

*Data are mean (SD) apart from triglycerides for which data are median (IQR), or number of participants (n).

Attachment A: SAS Code, provided by DCC and modified by RTI

```

/*****/
/*
/* Program: R:\05_Users\Norma\DPP\Update\getdata.sas
/* Author: Norma Pugh
/* Date: December 2012
/* Purpose: Merge DPP datasets (DPP, DPP Bridge, DPPOS) per DCC code.
/*****/

/*****/
/* DPP data */
/*****/
/* Datasets: S03 (Baseline info), F01, F02, F06, BASEDATA, EVENTS */
libname DPPREL1
'\\samba1.rtp.rti.org\niddk\03_Data_And_Tools\Studies\DPP\Official_Archive\v2.1\Data\DPP_Data_200
8\Form Data\Data';
libname DPPREL2
'\\samba1.rtp.rti.org\niddk\03_Data_And_Tools\Studies\DPP\Official_Archive\v2.1\Data\DPP_Data_200
8\Non-Form Data\Data';

proc sort data=DPPREL1.S03 out=s03; by release_id; run;
proc sort data=DPPREL2.basedata out=basedata; by release_id; run;

/* Use S03 data to get baseline height and merge with BASEDATA to estimate weight at baseline */
data S03; merge S03 basedata(keep=release_id BMI_CAT); by release_id;

if SOHGHT1>. then HEIGHT = MEAN(SOHGHT1,SOHGHT2,SOHGHT3);

*** Estimate weight at baseline from BMI categories;
select (bmi_cat);
  when (1) BMI=25;
  when (2) BMI=27;
  when (3) BMI=29;
  when (4) BMI=31;
  when (5) BMI=33;
  when (6) BMI=35;
  when (7) BMI=37;
  when (8) BMI=39;
  when (9) BMI=41;
  when (10) BMI=45;
otherwise;
end;

weight=(height/100)*(height/100)*bmi;

visit='BAS';

drop bmi_cat;
run;

/* Push together all DPP data from baseline through followup */

```

DPP Phase 1: ADDENDUM

```
data dpp_follow; set S03 DPPREL1.f01 DPPREL1.f02 DPPREL1.f06; run;
proc sort; by release_id; run;

/*****/
/* DPP-bridge data */
/*****/
/* Datasets: F01, F02, EVENTS */
libname DPPBR1
'\\samba1.rtp.rti.org\niddk\03_Data_And_Tools\Studies\DPPOS\Phase1\Official_Archive\DPP_Bridge_Of
ficial_Archive\DPP_BRIDGE_Data\Form_based';
libname DPPBR2
'\\samba1.rtp.rti.org\niddk\03_Data_And_Tools\Studies\DPPOS\Phase1\Official_Archive\DPP_Bridge_Of
ficial_Archive\DPP_BRIDGE_Data\non_form_based';

/* Push together DPP-bridge data */
data dppbr_follow; set DPPBR1.f01 DPPBR1.f02; run;
proc sort; by release_id; run;

/*****/
/* DPPOS data */
/*****/
/* Datasets: F01, F02, F06, EVENTS */
libname DPPOS1
'\\samba1.rtp.rti.org\niddk\03_Data_And_Tools\Studies\DPPOS\Phase1\Official_Archive\DPPOS_PHASE1_
Data\form-based';
libname DPPOS2
'\\samba1.rtp.rti.org\niddk\03_Data_And_Tools\Studies\DPPOS\Phase1\Official_Archive\DPPOS_PHASE1_
Data\non-form-based';

/* Push together DPPOS data */
data dppos_follow; set DPPOS1.f01 DPPOS1.f02 DPPOS1.f06; run;
proc sort; by release_id; run;

/*****/
/* Merge all visit data together from DPP+Bridge+DPPOS */
/*****/
data follow; set dpp_follow(in=indpp) dppbr_follow(in=inbridge) dppos_follow(in=indppos);

    if indpp then DPP=1;
    if inbridge then Bridge=1;
    if indppos then DPPOS=1;

    *** Compute weight at each followup visit;
    if QPWGHT1>. then WEIGHT = MEAN(QPWGHT1,QPWGHT2,QPWGHT3);
    else if APWGHT1>. then WEIGHT=MEAN(APWGHT1,APWGHT2,APWGHT3);
    label weight = "Current weight (kg)";

**** Define regularly-scheduled quarterly and semi-annual visits for DPP and DPPOS;
**** DPP and Bridge visits - assign based on VISIT as listed on form;
select (visit);
    when ('SCR') QUARTER=0;
    when ('BAS') QUARTER=0;
```

DPP Phase 1: ADDENDUM

```
when ('M03') QUARTER=1;
when ('M06') QUARTER=2;
when ('M09') QUARTER=3;
when ('Y01') QUARTER=4;
when ('M15') QUARTER=5;
when ('M18') QUARTER=6;
when ('M21') QUARTER=7;
when ('Y02') QUARTER=8;
when ('M27') QUARTER=9;
when ('M30') QUARTER=10;
when ('M33') QUARTER=11;
when ('Y03') QUARTER=12;
when ('M39') QUARTER=13;
when ('M42') QUARTER=14;
when ('M45') QUARTER=15;
when ('Y04') QUARTER=16;
when ('M51') QUARTER=17;
when ('M54') QUARTER=18;
when ('M57') QUARTER=19;
when ('Y05') QUARTER=20;
when ('M63') QUARTER=21;
when ('M66') QUARTER=22;
when ('M69') QUARTER=23;
when ('Y06') QUARTER=24;
otherwise;
end;

if mod(quarter,2)=0 then semi=quarter/2;

*** DPPOS Visits - must assign semi-annual visits based on days since randomization;
if substr(visit,3,1) in ('A','M')then semi = floor(daysrand/182.625);

label quarter = "Quarter of visit - DPP"
      semi     = "Semi-annual visit";

      keep release_id quarter semi visit weight dpp bridge dppos;
run;

proc sort; by release_id; run;

/*****
/* Combine complete events dataset */
*****/
proc sort data=DPPREL2.events out=dppevents; by release_id; run;
proc sort data=DPPBR2.events out=dppbrevents; by release_id; run;
proc sort data=DPPOS2.events out=dpposevents; by release_id; run;

/* Combine events datasets from all 3 time periods */
data events; merge dppevents(in=indpp keep=release_id diabf diabt diabv totaltim)
                dppbrevents(in=inbridge keep=release_id diabf diabt diabv
totaltim)
                dpposevents(in=indppos drop=randper);
by release_id;

length last_event $6.;

*** Keep the record from the latest the participant was in the study;
```

DPP Phase 1: ADDENDUM

```
if indppos
    or (inbridge and ~indppos)
    or (indpp and ~inbridge and ~indppos);

*** Label the visit type;
if indppos then last_event='DPPOS';
else if inbridge then last_event='BRIDGE';
else if indpp then last_event='DPP';
run;
proc sort data=events; by release_id; run;

/*****
/* Combine complete events dataset with baseline demographics */
*****/
proc sort data=DPPREL2.basedata out=dppbasedata; by release_id; run;
data events_demo; merge events dppbasedata; by release_id; run;

data all_data;
    merge follow events_demo ; by release_id;
run;

proc sort data=all_data; by release_id semi; run;

/* Sample table of variables over time by treatment group */
proc tabulate data=all_data;
    where .<semi<=20 and assign ne 'Troglitazone';
    class semi assign;
    var weight;
    tables semi='Semi-annual visit',assign=' '*weight=' *(n='N'*f=4.0 mean='Mean'*f=5.1
std='Standard Deviation'*f=5.1);
    title 'Diabetes Prevention Program';
    title2 'Weight at each semi-annual visit by treatment arm';
    title3 'DPP+Bridge+DPPOS Period';
run;

/* Sample Cox Proportional Hazards Model for the full DPP+Bridge+DPPOS period */
PROC PHREG DATA=events_demo; where assign ne 'Troglitazone';
class assign;
MODEL diabv*diabf(0)=assign
    /TIES=discrete ALPHA=0.05 RL;
title 'Diabetes Prevention Program';
title2 'Time to diabetes';
title3 'DPP+Bridge+DPPOS Period';
RUN;

/* Sample Cox Proportional Hazards Model for the DPP period */
data DPPevents_only; merge dpprel2.events dpprel2.basedata; by release_id; run;
PROC PHREG DATA=DPPevents_only; where assign ne 'Troglitazone';
class assign;
```


DPP Phase 1: ADDENDUM

```
MODEL diabv*diabf(0)=assign
  /TIES=discrete ALPHA=0.05 RL;
title 'Diabetes Prevention Program';
title2 'Time to diabetes';
title3 'DPP Period only';
RUN;
```

Attachment B: SAS Output, from code provided by DCC and modified by RTI.

Diabetes Prevention Program
 Weight at each semi-annual visit by treatment arm
 DPP+Bridge+DPPOS Period

1

	Lifestyle			Metformin			Placebo		
	N	Mean	Standard Deviation	N	Mean	Standard Deviation	N	Mean	Standard Deviation
Semi-annual visit									
0	1024	93.7	18.5	1027	93.9	18.2	1030	94.0	18.8
1	991	87.7	20.1	978	91.9	19.5	970	94.5	20.9
2	971	87.6	20.3	969	91.7	20.0	975	94.2	20.7
3	938	88.0	20.5	949	92.0	19.8	947	94.7	20.8
4	947	88.8	20.6	958	92.7	20.5	960	94.6	20.5
5	930	89.7	21.5	920	92.9	20.8	937	94.7	21.2
6	941	89.9	21.2	944	92.6	20.8	937	94.2	21.1
7	953	90.2	21.5	964	92.2	20.2	964	94.5	21.2
8	934	90.7	21.5	984	92.2	20.2	967	93.4	20.7
9	865	91.8	21.9	902	91.4	20.4	891	93.3	20.4
10	886	90.3	21.2	906	91.9	19.8	906	93.8	21.0
11	817	92.2	21.5	841	91.9	21.2	849	92.7	20.3
12	844	91.7	21.2	888	91.5	19.4	870	95.2	20.8
13	707	91.5	21.1	723	92.0	20.7	737	94.0	20.4
14	783	91.6	21.1	835	91.4	20.0	829	94.9	21.2
15	724	92.2	20.7	712	92.1	21.0	685	94.0	20.3
16	803	91.3	20.5	814	92.0	20.6	802	94.0	20.6
17	692	91.7	20.9	727	92.2	20.5	703	93.4	19.9

(Continued)

DPP Phase 1: ADDENDUM

Diabetes Prevention Program 2
 Weight at each semi-annual visit by treatment arm
 DPP+Bridge+DPPOS Period 18:24 Saturday, January 19, 2013

	Lifestyle			Metformin			Placebo		
	N	Mean	Standard Deviation	N	Mean	Standard Deviation	N	Mean	Standard Deviation
Semi-annual visit									
18	739	91.2	20.8	769	92.3	20.6	768	94.1	20.9
19	577	93.2	22.0	522	92.6	22.4	547	92.2	19.0
20	409	91.8	21.5	417	92.6	21.7	438	95.5	20.3

DPP Phase 1: ADDENDUM

Diabetes Prevention Program 3

Time to diabetes 18:24 Saturday, January 19, 2013
 DPP+Bridge+DPPOS Period

The PHREG Procedure

Model Information

Data Set	WORK.EVENTS_DEMO	
Dependent Variable	DIABV	Interval for diabetes
Censoring Variable	DIABF	Indicator of diabetes
Censoring Value(s)	0	
Ties Handling	DISCRETE	

Number of Observations Read	3081
Number of Observations Used	3081

Class Level Information

Class	Value	Design	
		Variables	
ASSIGN	Lifestyle	1	0
	Metformin	0	1
	Placebo	0	0

Summary of the Number of Event and Censored Values

Total	Event	Censored	Percent Censored
3081	1278	1803	58.52

Convergence Status

Convergence criterion (GCONV=1E-8) satisfied.

Model Fit Statistics

Criterion	Without	With
	Covariates	Covariates
-2 LOG L	10770.571	10735.563
AIC	10770.571	10739.563
SBC	10770.571	10749.869

DPP Phase 1: ADDENDUM

Diabetes Prevention Program 4
 Time to diabetes 18:24 Saturday, January 19, 2013
 DPP+Bridge+DPPOS Period

The PHREG Procedure

Testing Global Null Hypothesis: BETA=0

Test	Chi-Square	DF	Pr > ChiSq
Likelihood Ratio	35.0081	2	<.0001
Score	35.2889	2	<.0001
Wald	34.9538	2	<.0001

Type 3 Tests

Effect	DF	Wald	
		Chi-Square	Pr > ChiSq
ASSIGN	2	34.9538	<.0001

Analysis of Maximum Likelihood Estimates

Parameter	DF	Parameter Estimate	Standard Error	Chi-Square	Pr > ChiSq	Hazard Ratio	95% Hazard Ratio Confidence Limits
ASSIGN Lifestyle	1	-0.41428	0.07045	34.5816	<.0001	0.661	0.576 0.759
ASSIGN Metformin	1	-0.21957	0.06819	10.3669	0.0013	0.803	0.702 0.918

Analysis of Maximum Likelihood Estimates

Parameter	Label
ASSIGN Lifestyle	TREATMENT ASSIGNMENT Lifestyle
ASSIGN Metformin	TREATMENT ASSIGNMENT Metformin

DPP Phase 1: ADDENDUM

Diabetes Prevention Program

5

Time to diabetes 18:24 Saturday, January 19, 2013
 DPP Period only

The PHREG Procedure

Model Information

Data Set	WORK.DPPEVENTS_ONLY	
Dependent Variable	DIABV	Interval for diabetes
Censoring Variable	DIABF	Indicator of diabetes
Censoring Value(s)	0	
Ties Handling	DISCRETE	

Number of Observations Read	3081
Number of Observations Used	3081

Class Level Information

Class	Value	Design Variables	
ASSIGN	Lifestyle	1	0
	Metformin	0	1
	Placebo	0	0

Summary of the Number of Event and Censored Values

Total	Event	Censored	Percent Censored
3081	655	2426	78.74

Convergence Status

Convergence criterion (GCONV=1E-8) satisfied.

Model Fit Statistics

Criterion	Without Covariates	With Covariates
-2 LOG L	5286.570	5223.469
AIC	5286.570	5227.469
SBC	5286.570	5236.438

DPP Phase 1: ADDENDUM

Diabetes Prevention Program 6
 Time to diabetes 18:24 Saturday, January 19, 2013
 DPP Period only

The PHREG Procedure

Testing Global Null Hypothesis: BETA=0

Test	Chi-Square	DF	Pr > ChiSq
Likelihood Ratio	63.1013	2	<.0001
Score	62.7466	2	<.0001
Wald	60.6241	2	<.0001

Type 3 Tests

Effect	DF	Wald	
		Chi-Square	Pr > ChiSq
ASSIGN	2	60.6241	<.0001

Analysis of Maximum Likelihood Estimates

Parameter	DF	Parameter Estimate	Standard Error	Chi-Square	Pr > ChiSq	Hazard Ratio	95% Hazard Ratio Confidence Limits
ASSIGN Lifestyle	1	-0.79631	0.10327	59.4566	<.0001	0.451	0.368 0.552
ASSIGN Metformin	1	-0.36689	0.09255	15.7147	<.0001	0.693	0.578 0.831

Analysis of Maximum Likelihood Estimates

Parameter	Label
ASSIGN Lifestyle	TREATMENT ASSIGNMENT Lifestyle
ASSIGN Metformin	TREATMENT ASSIGNMENT Metformin

Attachment C: SAS Code, written by RTI.

```

/*****
*****/
/*
/* Program: R:\05_Users\Norma\DPP\Update\phase1.sas
/* Author:  Norma Pugh
/* Date:    March 2013
/* Purpose: Replicate select results from Lancet paper.
/*****
*****/
/* Libnames */
LIBNAME phase1
'R:\03_Data_And_Tools\Studies\DPPOS\Phase1\Official_Archive\DPPOS_PHASE1_Data
\non-form-based'; run;

/* Get baseline datasets */
data bl_dppos; set phase1.demographic(where=(assign^='Troglitazone'));
output; assign='Total'; output; run;
data diab; set phase1.events; keep release_id diabf; run;
data labs; set phase1.laboratory(where=(visit='01A')); keep release_id visit
g000 g120 hba1 chol chdl cldl trig; run;

/* Table 2 */
/* Merge data, Convert mg/dl measurements to mmol/L, Get stats */
proc sort data=diab; by release_id; run;
data table2; merge bl_dppos(in=keep) diab labs; by release_id; if keep;
  fpg=g000*0.055;
  pg120=g120*0.055;
  _chol=chol*0.0259;
  _chdl=chdl*0.0259;
  _cldl=cldl*0.0259;
  _trig=trig*0.0113;
  label fpg   = 'Fasting plasma glucose, mmol/L'
        pg120 = '2-h plasma glucose, mmol/L'
        _chol = 'Total cholesterol, mmol/L'
        _chdl = 'HDL cholesterol, mmol/L'
        _cldl = 'LDL cholesterol, mmol/L'
        _trig = 'Triglycerides, mmol/L';
  count=1;
run;

proc freq data=table2(where=(assign^='Total')); tables count / list missing;
run;
proc means data=table2 n mean std; class assign; var fpg hba1; run;

```


DPP Phase 1: ADDENDUM

```
proc freq data=table2; tables assign*sex / list missing; run;
proc means data=table2 n mean std; class diabf assign; var fpg pg120 hba1
_chol _chdl _cldl; run;
proc means data=table2 n median q1 q3; class diabf assign; var _trig; run;
```

Attachment D: SAS Output, from code written by RTI.

The SAS System

19:52 Tuesday, March 5, 2013 1

The FREQ Procedure

count	Frequency	Percent	Cumulative Frequency	Cumulative Percent
1	2572	100.00	2572	100.00

DPP Phase 1: ADDENDUM

The SAS System

19:52 Tuesday, March 5, 2013 2

The MEANS Procedure

TREATMENT ASSIGNMENT	N Obs	Variable	Label	N	Mean	Std Dev
Lifestyle	847	fpg	Fasting plasma glucose, mmol/L	795	5.9944465	1.1600652
		HBA1	HbA1c	796	5.9028894	0.6582456
Metformin	864	fpg	Fasting plasma glucose, mmol/L	828	5.9170169	0.9677466
		HBA1	HbA1c	822	5.8937956	0.6385489
Placebo	861	fpg	Fasting plasma glucose, mmol/L	816	6.2034743	1.3011884
		HBA1	HbA1c	815	6.0136196	0.7386810
Total	2572	fpg	Fasting plasma glucose, mmol/L	2439	6.0380935	1.1561584
		HBA1	HbA1c	2433	5.9369092	0.6818324

DPP Phase 1: ADDENDUM

The SAS System

19:52 Tuesday, March 5, 2013 3

The FREQ Procedure

ASSIGN	SEX	Frequency	Percent	Cumulative Frequency	Cumulative Percent
Lifestyle	1	283	5.50	283	5.50
Lifestyle	2	564	10.96	847	16.47
Metformin	1	296	5.75	1143	22.22
Metformin	2	568	11.04	1711	33.26
Placebo	1	280	5.44	1991	38.71
Placebo	2	581	11.29	2572	50.00
Total	1	859	16.70	3431	66.70
Total	2	1713	33.30	5144	100.00

DPP Phase 1: ADDENDUM

The SAS System 19:52 Tuesday, March 5, 2013 4

The MEANS Procedure

Indicator of diabetes	TREATMENT ASSIGNMENT	N Obs	Variable	Label	N	Mean
0	Lifestyle	500	fpg	Fasting plasma glucose, mmol/L	468	5.5669872
			pg120	2-h plasma glucose, mmol/L	461	7.6453579
			HBA1	HbA1c	469	5.6927505
			_chol	Total cholesterol, mmol/L	470	5.0765653
			_chdl	HDL cholesterol, mmol/L	470	1.3024945
			_cldl	LDL cholesterol, mmol/L	470	3.0983013
			Metformin	472	fpg	Fasting plasma glucose, mmol/L
	pg120	2-h plasma glucose, mmol/L			437	7.7903661
	HBA1	HbA1c			450	5.6864444
	_chol	Total cholesterol, mmol/L			451	5.0567596
	_chdl	HDL cholesterol, mmol/L			451	1.2806430
	_cldl	LDL cholesterol, mmol/L			451	3.0745769
	Placebo	415			fpg	Fasting plasma glucose, mmol/L
			pg120	2-h plasma glucose, mmol/L	381	7.6109318
			HBA1	HbA1c	389	5.7053985
			_chol	Total cholesterol, mmol/L	391	5.0868660
			_chdl	HDL cholesterol, mmol/L	391	1.2577066
			_cldl	LDL cholesterol, mmol/L	391	3.1066090
			Total	1387	fpg	Fasting plasma glucose, mmol/L
	pg120	2-h plasma glucose, mmol/L			1279	7.6846482
	HBA1	HbA1c			1308	5.6943425
_chol	Total cholesterol, mmol/L	1312			5.0728269	
_chdl	HDL cholesterol, mmol/L	1312			1.2816354	
_cldl	LDL cholesterol, mmol/L	1312			3.0926219	
1	Lifestyle	347			fpg	Fasting plasma glucose, mmol/L
			pg120	2-h plasma glucose, mmol/L	167	9.8077844
			HBA1	HbA1c	327	6.2042813
			_chol	Total cholesterol, mmol/L	327	5.0329165
			_chdl	HDL cholesterol, mmol/L	327	1.1545697
			_cldl	LDL cholesterol, mmol/L	327	3.0749716
			Metformin	392	fpg	Fasting plasma glucose, mmol/L
	pg120	2-h plasma glucose, mmol/L			130	9.6262692
	HBA1	HbA1c			372	6.1446237
	_chol	Total cholesterol, mmol/L			378	4.9882167
	_chdl	HDL cholesterol, mmol/L			378	1.2118185
	_cldl	LDL cholesterol, mmol/L			378	2.9883667
	Placebo	446			fpg	Fasting plasma glucose, mmol/L
			pg120	2-h plasma glucose, mmol/L	129	9.5380233
			HBA1	HbA1c	426	6.2950704

DPP Phase 1: ADDENDUM

The SAS System 19:52 Tuesday, March 5, 2013 5

The MEANS Procedure

Indicator of diabetes	TREATMENT ASSIGNMENT	N		Variable	Label	N	Mean
		Obs					
1	Placebo	446		_chol	Total cholesterol, mmol/L	425	5.0625054
				_chdl	HDL cholesterol, mmol/L	425	1.1637936
				_cldl	LDL cholesterol, mmol/L	425	3.0352362
Total		1185		fpg	Fasting plasma glucose, mmol/L	1129	6.5729141
				pg120	2-h plasma glucose, mmol/L	426	9.6707042
				HBA1	HbA1c	1125	6.2189333
				_chol	Total cholesterol, mmol/L	1130	5.0290924
				_chdl	HDL cholesterol, mmol/L	1130	1.1771894
				_cldl	LDL cholesterol, mmol/L	1130	3.0310564

Indicator of diabetes	TREATMENT ASSIGNMENT	N		Variable	Label	Std Dev
		Obs				
0	Lifestyle	500		fpg	Fasting plasma glucose, mmol/L	0.5204692
				pg120	2-h plasma glucose, mmol/L	1.7834891
				HBA1	HbA1c	0.3816164
				_chol	Total cholesterol, mmol/L	0.9409626
				_chdl	HDL cholesterol, mmol/L	0.3662162
				_cldl	LDL cholesterol, mmol/L	0.8093593
			Metformin		472	
	pg120	2-h plasma glucose, mmol/L				1.8775726
	HBA1	HbA1c				0.3420341
	_chol	Total cholesterol, mmol/L				0.8613667
	_chdl	HDL cholesterol, mmol/L				0.3519170
	_cldl	LDL cholesterol, mmol/L				0.7315862
Placebo		415				
				pg120	2-h plasma glucose, mmol/L	1.7934950
				HBA1	HbA1c	0.3825399
				_chol	Total cholesterol, mmol/L	0.9962135
				_chdl	HDL cholesterol, mmol/L	0.3284623
				_cldl	LDL cholesterol, mmol/L	0.8530078
			Total		1387	
	pg120	2-h plasma glucose, mmol/L				1.8193423
	HBA1	HbA1c				0.3685599
	_chol	Total cholesterol, mmol/L				0.9310265
	_chdl	HDL cholesterol, mmol/L				0.3505853
	_cldl	LDL cholesterol, mmol/L				0.7966768
1	Lifestyle	347		fpg	Fasting plasma glucose, mmol/L	1.5006354
				pg120	2-h plasma glucose, mmol/L	2.2197435

DPP Phase 1: ADDENDUM

The SAS System 19:52 Tuesday, March 5, 2013 6

The MEANS Procedure

Indicator of diabetes	TREATMENT ASSIGNMENT	N Obs	Variable	Label	Std Dev
1	Lifestyle	347	HBA1	HbA1c	0.8324220
			_chol	Total cholesterol, mmol/L	0.9455587
			_chdl	HDL cholesterol, mmol/L	0.2886661
			_cldl	LDL cholesterol, mmol/L	0.8131794
Metformin	392	fpg	Fasting plasma glucose, mmol/L	1.2077031	
		pg120	2-h plasma glucose, mmol/L	2.1484405	
		HBA1	HbA1c	0.8034280	
		_chol	Total cholesterol, mmol/L	0.8856462	
		_chdl	HDL cholesterol, mmol/L	0.2972724	
		_cldl	LDL cholesterol, mmol/L	0.7985581	
Placebo	446	fpg	Fasting plasma glucose, mmol/L	1.5598389	
		pg120	2-h plasma glucose, mmol/L	2.2454501	
		HBA1	HbA1c	0.8632083	
		_chol	Total cholesterol, mmol/L	1.3263873	
		_chdl	HDL cholesterol, mmol/L	0.3296488	
		_cldl	LDL cholesterol, mmol/L	0.8297001	
Total	1185	fpg	Fasting plasma glucose, mmol/L	1.4430084	
		pg120	2-h plasma glucose, mmol/L	2.2039594	
		HBA1	HbA1c	0.8365785	
		_chol	Total cholesterol, mmol/L	1.0870984	
		_chdl	HDL cholesterol, mmol/L	0.3082178	
		_cldl	LDL cholesterol, mmol/L	0.8146095	

DPP Phase 1: ADDENDUM

The SAS System 19:52 Tuesday, March 5, 2013 7

The MEANS Procedure

Analysis Variable : _trig Triglycerides, mmol/L

Indicator of diabetes	TREATMENT ASSIGNMENT	N Obs	N	Median	Lower Quartile	Upper Quartile
0	Lifestyle	500	470	1.2204000	0.8814000	1.8306000
	Metformin	472	451	1.3560000	0.9492000	1.9323000
	Placebo	415	391	1.3560000	0.9718000	1.8645000
	Total	1387	1312	1.2882000	0.9266000	1.8814500
1	Lifestyle	347	327	1.5594000	1.1300000	2.0792000
	Metformin	392	378	1.4690000	1.0735000	2.1809000
	Placebo	446	425	1.5255000	1.1413000	2.1357000
	Total	1185	1130	1.5142000	1.1074000	2.1357000